Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (BOS2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by European Organisation for Research and Treatment of Cancer - EORTC
Sponsor:
Collaborators:
Amgen
Roche Pharma AG
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:
NCT01508000
First received: January 9, 2012
Last updated: July 30, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)